NCT07455383Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Study sponsor: Alkermes, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05Estimated
Enrollment · participants150Estimated
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source